Cell News and Research

RSS

New findings may help identify treatments for diabetes and hyperinsulinemia

By investigating a rare and severe form of diabetes in children, University of Iowa researchers have discovered a new molecular mechanism that regulates specialized pancreatic cells and insulin secretion. The mechanism involves a protein called ankyrin, which UI researchers previously linked to potentially fatal human heart arrhythmias.

9 Sep 2009

TransIT-2020 transfection reagent released by Mirus Bio

From the transfection experts, Mirus Bio introduces its next generation transfection reagent, TransIT(R)-2020 Transfection Reagent.

9 Sep 2009

Rice researchers describe a new method to predict the efficacy of H1N1 vaccines

As manufacturers work furiously to make a vaccine to protect against 2009 influenza A (H1N1) virus, a Rice University bioengineer is trying to improve the process for future flu seasons. The goal is to shorten the time it takes to identify targeted flu strains and manufacture the vaccines for them.

9 Sep 2009

PKCiota oncogene essential for lung cancer stem cell proliferation

Scientists at the Mayo Clinic campus in Florida have found that the lung cancer oncogene PKCiota is necessary for the proliferation of lung cancer stem cells. These stem cells are rare and powerful master cells that manufacture the other cells that make up lung tumors and are resistant to chemotherapy treatment.

9 Sep 2009

URV’s biosensor can detect typhoid causing bacteria instantly

A research group from the Rovira i Virgili University (URV) in Tarragona has developed a biosensor that can immediately detect very low levels of Salmonella typhi, the bacteria that causes typhoid fever. The technique uses carbon nanotubes and synthetic DNA fragments that activate an electric signal when they link up with the pathogen.

9 Sep 2009

Research reveals new protective properties of vitamin C

Researchers at the University of Leicester and Institute for Molecular and Cellular Biology in Portugal studied new protective properties of vitamin C in cells from the human skin, which could lead to better skin regeneration.

9 Sep 2009

FDA approves ISTA's Bepreve for treating ocular itch

ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA) today announced the U.S. Food and Drug Administration (FDA) has approved Bepreve(TM) (bepotastine besilate ophthalmic solution) 1.5% as a twice-daily prescription eye drop treatment for ocular itching associated with allergic conjunctivitis in patients two years of age and older.

9 Sep 2009

Research study highlights unique aspects of tumor immunology

Immune responses are capable of killing tumors before they can be directed toward normal body tissue, according to new scientific findings published in Cancer Research, a journal of the American Association for Cancer Research.

9 Sep 2009

Cell Biosciences acquires Alpha Innotech for $17.9 million

Cell Biosciences, Inc. and Alpha Innotech Corp. today announced that they have entered into a definitive agreement providing for the acquisition of Alpha Innotech by Cell Biosciences for $1.50 per share, or approximately $17.9 million in cash.

9 Sep 2009

Major advance in understanding Friedreich's ataxia

University of Sydney researchers have made a significant advance in understanding the debilitating hereditary disease Friedreich's ataxia, offering hope that new forms of treatment will be developed.

8 Sep 2009

Roche RTS Protein Expression portfolio transferred to RiNA GmbH

Roche and RiNA GmbH of Berlin have agreed to transfer the complete Roche Applied Science RTS Protein Expression portfolio to RiNA GmbH, effective September 15, 2009.

8 Sep 2009

Preliminary results of Phase III Gvhd trials announced by Osiris Therapeutics

Osiris Therapeutics, Inc. (NASDAQ: OSIR) today announced preliminary results for two phase III trials evaluating Prochymal for the treatment of acute graft versus host disease (GvHD). GvHD, the most common complication of bone marrow transplantation, is a life-threatening disease for which there is currently no approved treatment. Prochymal showed significant improvements in response rates in difficult-to-treat liver and gastrointestinal GvHD, however neither trial reached its primary endpoint.

8 Sep 2009

Haemonetics acquires SEBRA's blood collection and processing business

Haemonetics Corporation, a global blood management solutions company, and Engineering and Research Associates Inc. (known as "SEBRA(R)"), a leading provider of blood and medical manufacturing technologies, announced today that Haemonetics has acquired the assets of SEBRA's blood collection and processing business for $12.5 million cash. The acquisition is expected to close within the next several weeks.

8 Sep 2009

eBioscience Corporation announces the acquisition of NatuTec GmbH

eBioscience Corporation, a leading global provider of innovative, high-quality cell analysis reagents announced today the acquisition of NatuTec GmbH, a leading distributor of high-quality biological research reagents located in Frankfurt am Main, Germany.

8 Sep 2009

Opexa Therapeutics' ongoing development program for Tovaxin to be presented

Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced that Neil K. Warma, Opexa’s president and chief executive officer, will deliver a corporate presentation at Rodman & Renshaw’s 11th Annual Healthcare Conference.

8 Sep 2009

Rosetta Genomics and AXA Diagnostics sign exclusive distribution agreement

Rosetta Genomics, Ltd. (NASDAQ: ROSG), a leading developer of microRNA-based molecular diagnostics, and AXA Diagnostics, a privately owned company that markets specialized diagnostic tests, announced today the signing of an exclusive distribution agreement in Italy for Rosetta Genomics’ three currently available diagnostic tests.

8 Sep 2009

RIKEN Yokohama Institute to purchase Genetic Analysis Systems from Helicos BioSciences

Helicos BioSciences Corporation (NASDAQ:HLCS) today announced that the RIKEN Yokohama Institute Omics Science Center (OSC) has agreed to purchase four Helicos™ Genetic Analysis Systems. The transaction represents the first multisystem sale of the Helicos system to a large genome center. Shipments are expected to take place in September, with one system remaining in Cambridge to be used in a scientific collaboration between the two parties that began last year.

8 Sep 2009

Protalix receives orphan drug designation for prGCD

Protalix BioTherapeutics, Inc. (NYSE-Amex:PLX), announced today that it has received notice from the U.S. Food and Drug Administration (FDA) that the FDA’s Office of Orphan Products Development has granted orphan drug designation to prGCD, the Company’s proprietary plant cell expressed recombinant form of glucocerebrosidase (GCD) for the treatment of Gaucher disease.

8 Sep 2009

Opexa Therapeutics releases Phase IIb TERMS clinical study results

Opexa Therapeutics, Inc., a company developing Tovaxin, a personalized T-cell immunotherapy for multiple sclerosis (MS), today announced results from further analysis of the double-blind, placebo-controlled, 52-week Phase IIb TERMS clinical study of 150 patients with Relapsing Remitting MS (RRMS).

8 Sep 2009

Working mothers suffer from vision impairment as they age

For working mothers -- the ultimate multitaskers -- seeing clearly is essential to getting the job done. Yet, new research reveals that as they age, changes in their vision are impacting the ability of most moms to perform everyday activities at home and on the job.

8 Sep 2009